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Abstract
Background: The recent emergence of azithromycin-resistant (AZM-R) N. gonorrhoeae isolates that have coevolved
decreased susceptibility to extended-spectrum cephalosporins has caused great concern. Here we investigated the
prevalence of decreased susceptibility to ceftriaxone (CROD) in AZM-R isolates and genetically characterized AZM-R
isolates in Guangzhou, China from 2009 to 2013.
Methods: The minimum inhibitory concentration (MIC) of AZM and ceftriaxone was determined using an agar-dilution
method. All AZM-R isolates were screened for mutations in 23S rRNA, mtrR and penA genes and genotyped using N.
gonorrhoeae multi-antigen sequence typing (NG-MAST).
Results: Of the 485 identified N. gonorrhoeae isolates, 445 (91.8 %) were isolated from male urethritis subjects, and 77
(15.9 %) were AZM-R (MIC≥ 1 mg/L), including 33 (6.8 %) with AZM low-level resistant (AZM-LLR, MIC = 1 mg/L) and
44 (9.1 %) with AZM middle-level resistant (AZM-MLR, MIC≥ 2 mg/L). Significantly more CROD (MIC≥ 0.125 mg/L)
showed in AZM-MLR isolates (43.2 %, 19/44) as compared with that in AZM-LLR isolates (18.2 %, 6/33) (p < 0.05). For
the 23S rRNA, mtrR, penA or combined 23S rRNA/MtrR/penA mutations, no significant difference was found between
AZM-LLR isolates and AZM-MLR isolates (P > 0.05); similar results were detected between combined AZM-LLR/CROD
isolates and combined AZM-MLR/CROD isolates (P > 0.05). No mutation A2059G or AZM high-level resistant (AZM-HLR,
MIC≥ 256 mg/L) isolate was detected. Among 77 AZM-R isolates, 67 sequence types (STs) were identified by NG-MAST,
of which 30 were novel. Most STs were represented by a single isolate.
Conclusions: The AZM-R together CROD isolates are now present in Guangzhou, China, which deserve continuous
surveillance and the mechanism of concurrent resistance needs further study.
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Background
The global spread of multidrug-resistant Neisseria gonor-
rhoeae (N. gonorrhoeae) is a growing public health
threat. Worryingly, clinical treatment failures with the
extended-spectrum cephalosporins (ESCs) [1], the last
remaining options for empirical first-line monotherapy,
have recently been reported. Accordingly, dual anti-
microbial therapies have been introduced in several
countries [2, 3], including China [4]. These consist of
ceftriaxone (250–500 mg intramuscularly) or cefixime
(400 mg orally, if ceftriaxone is not an option) together
with azithromycin (AZM, 1–2 g orally) for treatment of
uncomplicated gonorrhea. AZM was recommended for
patients with gonorrhea or coinfection with Chlamydia
trachomatis in China around the year 2000 [5], and since
then has been broadly used because of its wide availabil-
ity and ease of administration. In China, AZM-resistant
(AZM-R) N. gonorrhoeae were first identified during
2001–2003 [6], and the first AZM-R isolates were identi-
fied in Guangzhou in 2009 [7]. Treatment failures with
2 g of AZM and high-level AZM resistant N. gonor-
rhoeae isolates with a minimum inhibitory concentration
(MIC) ≥ 256 mg/L have been verified in several countries
[8, 9]. Recently, a surveillance of antimicrobial resistance
in gonococci from Canada resulted in two high-level
AZM-R isolates (MIC ≥ 2048 mg/L), which may be due
to mutation A2143G (N. gonorrhoeae numbering) in the
four copies of the 23S rRNA gene [9].
Mutations at various genes such as 23S rRNA, mtrR
and penA (encoding penicillin-binding protein 2, PB
P2), have been identified associating with chromosom-
ally mediated resistance to AZM [10, 11] and ESCs [12]
in N. gonorrhoeae. Globally, AZM-R together decreased
susceptibility to ESCs in N. gonorrhoeae has only rarely
been reported [9, 13]. In this study, we investigated the
prevalence of decreased susceptibility to ceftriaxone
(CROD) in AZM-R N. gonorrhoeae isolates, and the
molecular characteristics of AZM-R N. gonorrhoeae
isolates from January 2009 to November 2013 in
Guangzhou, China.
Methods
Gonococcal isolates and susceptibility testing
Clinical N. gonorrhoeae isolates were consecutively col-
lected from urethral or cervical specimen of one per pa-
tient with gonorrhea attending sexually transmitted
infection (STI) clinics in Guangzhou, China between
January 2009 and November 2013. The demographic
and clinical information of patients such as gender, age,
and symptoms was collected by completing a question-
naire. Each isolate was cultured, verified, and preserved
as described [14]. MIC for AZM and ceftriaxone were
determined by the agar dilution method, according to
recommendations from the WHO [15]. Antimicrobial
susceptibility for AZM was interpreted using the
European Committee on Antimicrobial Susceptibility
Testing (EUCAST) guidelines (http://www.eucast.org/),
and ceftriaxone susceptibility was interpreted according to
criteria defined by WHO in 2012 [15]. Briefly, isolates
with MIC ≥ 1.0 mg/L for AZM were classified as resistant,
and isolates with MIC ≥ 0.125 mg/L for ceftriaxone were
classified as having decreased susceptibility. N. gonor-
rhoeae ATCC 49226 and strains G, L, and P of the 2008
WHO N. gonorrhoeae reference strain panel were used
as quality control strains. To compare with a previous
report [5] and better analyze the results, AZM-R N.
gonorrhoeae isolates (MIC ≥ 1.0 mg/L) were divided
into AZM low-level resistant (AZM-LLR) N. gonor-
rhoeae isolates (MIC = 1.0 mg/L), AZM middle-level
resistant (AZM-MLR) N. gonorrhoeae isolates (MIC ≥
2.0 mg/L), and AZM high-level resistant (AZM-HLR)
N. gonorrhoeae isolates (MIC ≥ 256 mg/L) in this study
based on the previous studies [9, 10].
Sequence-based molecular epidemiologic studies
Bacterial genome DNA from each identified AZM-R iso-
late was extracted using the TIANamp Bacterial DNA
kit (TIANGEN, Beijing, China). As previously described,
mutations in the four alleles of the 23S rRNA [16], mtrR
and penA genes [12], and polymorphisms in porB and
tbpB [17] were amplified by PCR. The PCR products
were purified and sequenced by Shenggong Co., Ltd.
(Shanghai, China). DNA sequences were aligned using
BLAST and GenBank programs (http://www.ncbi.nlm.-
nih.gov) to identify mutations in the 23S rRNA gene.
DNA sequences of mtrR and penA genes were translated
into deduced amino acid sequences, which were then
aligned with their respective prototypes in N. gonor-
rhoeae using Proteomics and Sequence Tools (http://
ca.expasy.org/). N. gonorrhoeae isolates were typed using
the N. gonorrhoeae multi-antigen sequence typing (NG-
MAST) method [17]. NG-MAST allele numbers of porB
and tbpB and STs were obtained using a publicly access-
ible database on the NG-MAST website (www.ng-mast.-
net). A phylogenetic tree was created using ClustalX
software (version 1.83; http://www.clustal.org/download/
1.X/ftp-igbmc.u-strasbg.fr/pub/ClustalX. html) and Mega
software (version 6.0.5; http://www.megasoftware.net/
mega.php) based on the more variable segments of porB
(490 bp) and tbpB (390 bp) as analyzed by NG-MAST.
Statistical analysis
Statistical significance was assessed using SPSS 13.0
(SPSS Inc, Chicago, IL). Chi-square tests were used for
statistical analyses. A P-value < 0.05 was considered to
be significant.
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Ethics approval
The study protocol was approved by the Medical Ethics
Committee at the Institute of Dermatology, the Chinese
Academy of Medical Sciences & Peking Union Medical
College and the National Center for Sexually Transmit-
ted Disease Control, Nanjing, China (approval number
2011-KY-003). Written informed consent was obtained
from all participating subjects.
Results
Antimicrobial susceptibility testing
A total of 485N. gonorrhoeae isolates were identified in
Guangzhou from 2009 to 2013 (Table 1). Of these, the
mean age of the patients was 31.6 years (range from 17
to 69 years), 91.8 % (445/485) isolates were isolated
from male patients with urethritis. Among all the iso-
lates, 15.9 % (77/485) showed AZM-R, including 6.8 %
(33/485) AZM-LLR and 9.1 % (44/485) AZM-MLR.
The proportion of AZM-LLR isolates decreased from
14.0 % (24/171) in 2009–2010 to 2.9 % (9/314) in
2011–2013 (p < 0.05), whereas AZM-MLR isolates in-
creased from 4.7 % (8/171) in 2009–2010 to 11.5 % (36/
314) in 2011–2013 (p < 0.05). In the 2011–2013 study
period, seven isolates with MIC > 8 mg/L appeared for
the first time and accounted for 2.2 % (7/314) of the
examined isolates (Fig. 1). The percentage of CROD
isolates was 22.3 % (108/485) in all identified N.
gonorrhoeae isolates, 18.2 % (6/33) in AZM-LLR iso-
lates, and 43.2 % (19/44) in AZM-MLR isolates which
was a significant increase compared with the percent-
age of all identified N. gonorrhoeae isolates or AZM-
LLR isolates (both p < 0.05, Table 2).
23S rRNA, mtrR and penA mutations in AZM-R N. gonor-
rhoeae isolates
Thirty-two of the 33 AZM-LLR isolates (97.0 %) con-
tained the wild-type sequence in domain V of all four
23S rRNA alleles, except one isolate (3.0 %, 1/33) that
contained mutation C2611T (Escherichia coli number-
ing; also known as C2599T, N. gonorrhoeae number-
ing) in a single allele (Table 2 and Additional file 1:
Table S1, S2). Thirty-eight of the 44 AZM-MLR isolates
(86.4 %) contained the wild-type sequence in all four 23S
rRNA alleles, whereas only one isolate (2.2 %, 1/44; its
AZM MIC = 2 mg/L) contained mutation C2611T in a
single allele and five isolates (11.4 %, 5/44; their AZM
MICs = 4, 8, 8, 8 and 64 mg/L, respectively) contained
mutation C2611T in all four alleles. All seven AZM-R iso-
lates that contained the mutation C2611T showed reduced
susceptibility to ceftriaxone (MIC ≥ 0.125 mg/L).
The presence of a single nucleotide deletion (A) in
the 13 bp inverted repeat of the mtrR promoter did not
different between AZM-LLR (87.9 %, 29/33) and AZM-
MLR (95.5 %, 42/44) isolates (P > 0.05) (Table 2 and
Additional file 1: Table S1, S2). A wild type (WT) in the
coding region of mtrR only displayed in combined
AZM-LLR/susceptibility to ceftriaxone (CROS) (n = 2)
and combined AZM-MLR/CROS (n = 2), but not in
combined AZM-LLR/CROD or combined AZM-MLR/
CROD isolates. The combined mutations (double or
triple) such as A39T/F62L, A40D/T86A, T86A/H105Y,
A40D/T86A/H105Y or D79N/T86A/H105Y were only
present in AZM-MLR isolates (Table 2).
All the AZM-R isolates (n = 77) in this study had an
Asp-346 insertion and contained F504L, A510V and
A516G mutations in PBP2 (data shown in Additional file
1: Table S1-S3). Thirteen mutation patterns in this study
Table 1 The resistance rates for AZM in N. gonorrhoeae isolated
in Guangzhou, China between 2009 and 2013
MIC
Year 1 mg/L ≥ 2 mg/L Total
2009 19.3 % (17/88) 4.5 % (4/88) 23.9 % (21/88)
2010 8.4 % (7/83) 4.8 % (4/83) 13.3 % (11/83)
2011 0.9 % (1/114) 7.9 % (9/114) 8.8 % (10/114)
2012 2.0 % (2/100) 17.0 % (17/100) 19.0 % (19/100)
2013 6.0 % (6/100) 10.0 % (10/100) 16.0 % (16/100)
Total 6.8 % (33/485) 9.1 % (44/485) 15.9 % (77/485)
Fig. 1 Distribution of MIC of AZM-R N. gonorrhoeae isolates during 2009 and 2010 (n = 171) versus 2011–2013 (n = 314)
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Table 2 Characteristics of N. gonorrhoeae isolates with AZM-R and CROD identified in Guangzhou in 2009-2013
AZM-LLR (n = 33) AZM-MLR (n = 44)
Totalc CROD Totalc CROD
n (%) n (%) n (%) n (%) P
Antimicrobial resistance 33 (100.0) 6 (18.2) 44 (100) 19 (43.2) b < 0.05
23 S rRNA
WT 32 (97.0) 5 (15.2) 38 (86.3) 13 (29.5) a, b > 0.05
C2611TS 1 (3.0) 1 (3.0) 1 (2.3) 1 (2.3)
C2611TAll 0 (0.0) 0 (0.0) 5 (11.4) 5 (11.4)
mtrR
Deletiona
Yes 29 (87.9) 6 (18.2) 42 (95.5) 19 (43.3) a > 0.05, b: ND
No 4 (12.1) 0 (0.0) 2 (4.5) 0 (0.0)
Mutations
WTb 2 (6.1) 0 (0.0) 2 (4.5) 0 (0.0) a, b > 0.05
A39T 7 (21.2) 4 (12.1) 6 (13.6) 4 (9.1)
G45D 8 (24.2) 1 (3.0) 5 (11.3) 2 (4.5)
H105Y 16 (48.5) 1 (3.0) 26 (59.1) 11 (25.0)
A39T/ F62L 0 (0.0) 0 (0.0) 1 (2.3) 0 (0.0)
A40D/T86A 0 (0.0) 0 (0.0) 1 (2.3) 0 (0.0)
A40D/T86A/H105Y 0 (0.0) 0 (0.0) 1 (2.3) 1 (2.3)
D79N/T86A/H105Y 0 (0.0) 0 (0.0) 1 (2.3) 1 (2.3)
T86A/ H105Y 0 (0.0) 0 (0.0) 1 (2.3) 0 (0.0)
Mutation patterns in PBP2
II or XIV 3 (9.1) 0 (0.0) 4 (9.1) 0 (0.0) a, b > 0.05
V 6 (18.2) 1 (3.0) 8 (18.2) 3 (6.8)
VII 0 (0.0) 0 (0.0) 1 (2.3) 0 (0.0)
VIII 0 (0.0) 0 (0.0) 1 (2.3) 1 (2.3)
XII 2 (6.1) 0 (0.0) 2 (4.6) 1 (2.3)
XIII 2 (6.1) 0 (0.0) 0 (0.0) 0 (0.0)
XVII 2 (6.1) 1 (3.0) 0 (0.0) 0 (0.0)
XVIII 5 (15.2) 2 (6.1) 13 (29.4) 10 (22.6)
XXI 7 (21.2) 1 (3.0) 8 (18.2) 3 (6.8)
XXVII 4 (12.2) 0 (0.0) 6 (13.6) 1 (2.3)
New 1d 1 (3.0) 0 (0.0) 0 (0.0) 0 (0.0)
New 2d 1 (3.0) 1 (3.0) 0 (0.0) 0 (0.0)
New 3d 0 (0.0) 0 (0.0) 1 (2.3) 0 (0.0)
23rRNA/mtrR/penA mutation patterns
WT/A-;H105Y/XVIII 2 (6.1) 0 (0.0) 4 (9.1) 3 (6.8) a, b > 0.05
WT/A-;H105Y/V 6 (18.2) 1 (3.0) 6 (13.6) 3 (6.8)
WT/A-;H105Y/XXI 2 (6.1) 0 (0.0) 6 (13.6) 2 (4.5)
WT/A-;G45D/XXI 4 (12.1) 3 (9.1) 0 (0.0) 0 (0.0)
WT/A-;A39T/XVIII 3 (9.1) 3 (9.1) 5 (11.4) 3 (6.8)
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included three new mutation patterns (New 1: A501V,
F504L A501V, A516G, H541N, P552V, I556V, I566V;
New 2: F504L, A501V, A516G, Y554H; New 3: A501V,
F504L, A510V, A516G, H541N, I566V) were shown in
Table 2. The patterns V (18.2 %), XVIII (15.2 %) and
XXI (21.2 %) were the most prevalent in AZM-LLR iso-
lates, similar to the most prevalent patterns (V, 18.2 %;
XVIII, 29.4 %; XXI, 18.2 %) in AZM-MLR isolates. No
different mutation patterns were found between
AZM-LLR isolates and AZM-MLR isolates or between
combined AZM-LLR/CROD isolates and combined
AZM-MLR/CROD isolates (both P > 0.05).
In addition, combined 23S rRNA/mtrR/penA mutation
patterns had no significant association with AZM-MLR
isolates or combined AZM-MLR/CROD isolates (Table 2).
NG-MAST and phylogenetic analysis based on porB and
tbpB DNA sequences
A total of 67 STs (29 STs in AZM-LLR isolates and 38
STs in AZM-MLR isolates) were identified by NG-
MAST among the 77 AZM-R isolates, of which 30 STs
(15 STs in AZM-LLR isolates and 15 STs in AZM-MLR
isolates) were first identified by the current study
(Table 3 and Additional file 1: Table S1, S2 and S3). The
most prevalent STs were ST1766 (n = 3), ST1866 (n = 2),
and ST421 (n = 2) in AZM-LLR isolates and ST1766 (n =
3), ST6987 (n = 2), ST1055 (n = 2), ST304 (n = 2), and a
new ST consisting of porB allele 822 and tbpB allele 156
(n = 2) in AZM-MLR isolates. Of the remaining STs, most
were represented by a single isolate. The phylogenetic
tree, built from DNA sequences of por (490 bp) and
tbpB (390 bp), displayed the significant diversity of
strains with 29 different STs in AZM-LLR isolates
(Additional file 2: Figure S1), as well as 38 different STs
in AZM-MLR isolates (Additional file 3: Figure S2).
Discussion
The present study combines antimicrobial susceptibil-
ity determinations with molecular-based analysis of
AZM-R in N. gonorrhoeae isolated from 2009 to 2013
in Guangzhou, China. As observed in other countries
worldwide [9, 13, 18], an upward shift in MIC by year
and a high percentage of AZM-R were identified in
this study, which was also in line with a previous
report in two Chinese cities, Nanjing and Chongqing,
between 2008 and 2009 [5]. The WHO recommends
discontinuation of the empirical use of an antibiotic
once 5 % of locally acquired gonococcal isolates are
resistant [19]. Accordingly, AZM has not been recom-
mended as a monotherapy for gonococcal urethritis or
cervicitis in China, as well as in many other countries
worldwide. To improve treatment efficacy and to delay
the further selection of cephalosporin-resistant N.
gonorrhoeae, most current guidelines now recommend
ESCs and AZM in combination as the first-line treat-
ment for gonorrhea [2–4, 9]. However, more recently,
AZM-R N. gonorrhoeae has been rarely and sporadically re-
ported to also have reduced susceptibility to ESCs [9, 13],
threatening the future efficacy of current therapeutic rec-
ommendations. Similarly, the present study showed that
the prevalence of combined AZM-MLR/CROD isolates sig-
nificantly increased as compared with that in all identified
N. gonorrhoeae isolates.
Previous studies investigating AZM-R and CROD have
focused on the mutations of three genes: 23S rRNA,
mtrR and penA [9–12]. Mutations at various positions
within the central loop of domain V of the 23S rRNA
gene are thought to lead to resistance by reducing the
ability of the 23S rRNA protein to bind the antibiotics
such as AZM [10]. Previous reports have shown that the
mutation C2611T in any of the four alleles of the 23S
rRNA can result in a lower level of resistance to AZM
[10]. In addition, the mutation A2059G (Escherichia coli
numbering) in at least three of the four alleles can con-
fer AZM-HLR, and AZM-sensitive isolates containing
this single allele mutation can quickly develop high-level
resistance in the presence of erythromycin [10]. In the
current study, only seven AZM-R isolates contained mu-
tation C2611T, whereas the remaining large number of
AZM-R isolates contained four wild-type alleles. These
findings contrast, however, with other reports from
Canada [9], the United States [11, 20] and the United
Kingdom [10], which most of the AZM-MLR isolates
contained this mutation was more than 80 %. Notably,
all the above-mentioned seven AZM-R isolates that
contained the mutation C2611T showed reduced
susceptibility to ceftriaxone. The mutation A2059G,
which is linked to AZM-HLR, was not detected in the
Table 2 Characteristics of N. gonorrhoeae isolates with AZM-R and CROD identified in Guangzhou in 2009-2013 (Continued)
C2611TAll/A-;H105Y/XVIII 0 (0.0) 0 (0.0) 2 (4.5) 2 (4.5)
C2611TAll/A-;G45D/XXI 0 (0.0) 0 (0.0) 2 (4.5) 2 (4.5)
Other patterns 16 (48.5) 2 (6.1) 17 (38.6) 2 (4.5)
AZM azithromycin, CROD decreased susceptibility to ceftriaxone, CROS susceptible to ceftriaxone, C2611TS mutation C2611T in a single allele, C2611TAll C2611T
mutations in all four alleles, aAdenine (A) deletion in the 13-bp inverted repeat (5’-AAAAAGACTTTTT-3’) within the -35 to -10 positions of themtrR promoter. bUsing mtrR from
N. gonorrhoeae FA1090 as a template. cIncluding CROS and CROD; dNew polymorphism patterns of PBP2: New 1 (A501V, F504L, A510V, A516G, H541N, P552V, I556V, I566V),
New 2 (F504L, A510V, A516G, Y554H), New 3 (A501V, F504L, A510V, A516G, H541N, I566V). a: the AZM-LLR isolates were compared to the AZM-MLR isolates; b: the combined
AZM-LLR/CROD isolates were compared to the combined AZM-MLR/CROD isolates; ND not determined (because of a small number of isolates)
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present study. In the mtrR gene, specific mutations in
the promoter or coding region can lead to decrease
the MtrCDE efflux pump repression and subsequently
increase export of the antimicrobials [20]. Loss of the
MtrCDE efflux pump can significantly increase sus-
ceptibility to AZM, ESCs, penicillin, ciprofloxacin, and
solithromyc in N. gonorrhoeae isolates [21]. In this
study, a single nucleotide deletion in the mtrR pro-
moter showed over 85 % in AZMR-R isolates, but not
significantly difference between combined AZMR-R/
CROS isolates and combined AZMR-R/CROD isolates,
in line with a previous report that such a deletion may
not implicate in CROD [12]. H105Y, the most preva-
lent single mutation, was not significantly difference
in AZM-LLR isolates as compared to AZM-MLR iso-
lates. Interestingly, the combined mutation in mtrR
was only observed in AZM-MLR isolates, but not in in
AZM-LLR isolates. Mutation in penA has been associ-
ated with decreased susceptibility or resistance to a
number of beta-lactam agents, especially to ESCs [22].
The mutations G545S, I312M, and V316T in mosaic
alleles of PBP2 were early suggested as important for
the increased ESCs resistance [23]. However, a recent
study revealed that these three mutations had only a
little to effect on resistance, and their capacity to in-
crease resistance to ESCs was dependent on the pres-
ence of other mutations in the mosaic alleles [24].
Mutation patterns XIII, XVII and XVIII have been
reported to only present in CROD isolates in China
[12] and Australia [22]. These three patterns con-
tained G542S, P551S and/or P551L mutations, which
have been associated with increased MIC of CRO [25].
However, their effects on the ceftriaxone MIC have
not yet been proven by site-directed penA mutations
in isogenic strain backgrounds [26] and the present
study showed that these three patterns were present in
both CROS and CROD isolates (data not shown). The
most prevalent mutation pattern in AZMR-R isolates
from Canada was XXXIV, which was showed to AZM-
R together with reduced susceptibility to ESCs [9]. By
comparison, this study revealed the most prevalent
mutation patterns (V, XVIII and XXI) were the same
in AZMR-LLR, AZMR-MLR, and combined AZMR-R/
CROD isolates, respectively. Overall, the results of
our study showed that the mutations of these three
genes had the considerable diversity, and that either
one of these three genes alone or combined muta-
tion patterns of these three genes cannot account for
AZM-MLR or combined AZM-R/CROD in our N.
gonorrhoeae isolates.
NG-MAST analysis and the resulting development of a
phylogenetic tree in this study also indicated a high
degree of genetic diversity of N. gonorrhoeae in
Guangzhou from 2009 to 2013. This observation may
be due to the highly limited epidemiologic information
of this study because our data do not represent the
whole country, or the flow of large numbers of tem-
porary population in Guangzhou, which lead to great
Table 3 NG-MAST STs and N. gonorrhoeae isolated with AZM-R
and CROD identified in Guangzhou in 2009-2013
AZM-LLR (n = 33) AZM-MLR (n = 44)
Totalb CROD Totalb CROD
NG-MAST ST n (%) n (%) n (%) n (%)
270 0 (0.0) 0 (0.0) 1 (2.3) 1 (2.3)
304 0 (0.0) 0 (0.0) 2 (4.5) 0 (0.0)
421 2 (6.1) 0 (0.0) 0 (0.0) 0 (0.0)
1053 1 (3.0) 0 (0.0) 1 (2.3) 1 (2.3)
1055 0 (0.0) 0 (0.0) 2 (4.5) 0 (0.0)
1056 0 (0.0) 0 (0.0) 1 (2.3) 0 (0.0)
1412 1 (3.0) 0 (0.0) 0 (0.0) 0 (0.0)
1731 1 (3.0) 0 (0.0) 0 (0.0) 0 (0.0)
1766 3 (9.1) 0 (0.0) 3 (6.8) 0 (0.0)
1866 2 (6.1) 0 (0.0) 1 (2.3) 0 (0.0)
1972 1 (3.0) 1 (3.0) 0 (0.0) 0 (0.0)
2103 1 (3.0) 0 (0.0) 0 (0.0) 0 (0.0)
2384 0 (0.0) 0 (0.0) 1 (2.3) 1 (2.3)
3079 1 (3.0) 0 (0.0) 0 (0.0) 0 (0.0)
3252 0 (0.0) 0 (0.0) 1 (2.3) 1 (2.3)
3356 0 (0.0) 0 (0.0) 1 (2.3) 1 (2.3)
3460 1 (3.0) 0 (0.0) 0 (0.0) 0 (0.0)
4313 0 (0.0) 0 (0.0) 1 (2.3) 1 (2.3)
4539 1 (3.0) 0 (0.0) 0 (0.0) 0 (0.0)
5061 0 (0.0) 0 (0.0) 1 (2.3) 1 (2.3)
5062 0 (0.0) 0 (0.0) 1 (2.3) 0 (0.0)
5179 1 (3.0) 1 (3.0) 0 (0.0) 0 (0.0)
5990 0 (0.0) 0 (0.0) 1 (2.3) 0 (0.0)
6987 0 (0.0) 0 (0.0) 2 (4.5) 1 (2.3)
7101 0 (0.0) 0 (0.0) 1 (2.3) 1 (2.3)
8776 1 (3.0) 0 (0.0) 0 (0.0) 0 (0.0)
9176 0 (0.0) 0 (0.0) 1 (2.3) 1 (2.3)
9944 1 (3.0) 0 (0.0) 0 (0.0) 0 (0.0)
10199 0 (0.0) 0 (0.0) 1 (2.3) 1 (2.3)
10205 0 (0.0) 0 (0.0) 1 (2.3) 1 (2.3)
10337 0 (0.0) 0 (0.0) 1 (2.3) 0 (0.0)
10352 0 (0.0) 0 (0.0) 1 (2.3) 0 (0.0)
10359 0 (0.0) 0 (0.0) 1 (2.3) 0 (0.0)
11181 0 (0.0) 0 (0.0) 1 (2.3) 0 (0.0)
Newa 15 (45.5) 4 (12.1) 16 (36.4) 7 (15.9)
AZM azithromycin, CRODdecreased susceptibility to ceftriaxone, CROS susceptible
to ceftriaxone, aNot found in the NG-MAST database (http://www.ng-mast.net);
bIncluding CROS and CROD
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opportunity for transport of new STs [27]. Also, AZM
is extensively used in China [5] and has long elimin-
ation half-life. Thus we postulate that the diversity of STs
developed, in part, in response to antibiotic pressure.
Some STs that were observed in the current study
(ST3356, ST1866, ST1766, and ST4313) had been noted
in a previous report of emerging AZM-R N. gonorrhoeae
in Nanjing and Chongqing, China [5], but these did not
include STs (ST470, ST649, ST3158, ST1704, ST359, and
ST696) that were reported previously in other countries
and have been shown to account for most of the resistance
or high-level resistance to AZM [9, 18, 28–30].
Conclusions
AZM-R N. gonorrhoeae isolates are increasing and, in
combination with CROD, have now been detected in
Guangzhou. The combined AZM-R/CROD in N. gonor-
rhoeae is a relatively new phenomenon, and the mechan-
ism for the emergence of these AZM-R/CROD isolates
remains unknown and needs further studied. Therefore,
antimicrobial susceptibility/resistance and the molecu-
lar epidemiology of AZM-R and/or CROD deserve con-
tinuous surveillance, which will be critical in providing
valuable information for current and future therapeutic
options in China.
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